Merck & Co., Inc. (MRK) Stock: Financial Analysis, Keytruda Risks, Dividend Outlook and 2026 Investment Review
 |
| Merck & Co., Inc. (MRK) |
Merck & Co., Inc. (NYSE: MRK) Stock Analysis 2026
Worldreview1989 - Merck & Co., Inc. (NYSE: MRK) remains one of the most closely watched pharmaceutical stocks in the United States. The company combines a blockbuster oncology franchise, a large vaccine business, Animal Health operations, and an expanding pipeline designed to reduce dependence on its flagship cancer drug, KEYTRUDA.
For American investors, however, MRK presents an unusual combination of strengths and risks. The company generates tens of billions of dollars in annual revenue and has a long-established dividend, but a substantial portion of its earnings power is tied to KEYTRUDA. At the same time, Merck is attempting to build the next generation of growth products before the company's most important exclusivity period becomes a larger financial issue.
As of the September 4, 2026 market close, MRK traded around $150.33 per share, according to market data. The stock had recently reached a 52-week high of approximately $156.92 on August 25.
The central question for investors is therefore not simply whether Merck is a good pharmaceutical company.
It is:
Can Merck successfully replace enough of KEYTRUDA's future revenue and earnings while maintaining its dividend and shareholder returns?
What Is Merck & Co.?
Merck & Co., Inc. is a major U.S. healthcare and pharmaceutical company headquartered in Rahway, New Jersey.
Its principal businesses include:
Prescription pharmaceuticals
Oncology
Vaccines
Animal Health
HIV and infectious diseases
Cardiometabolic medicine
Immunology and other therapeutic areas
Merck generated approximately $65.0 billion of revenue in 2025 and spent approximately $15.8 billion on research and development, demonstrating the scale of its pharmaceutical innovation platform.
The company operates under the name MSD outside the United States and Canada.
For investors, Merck's business model has three particularly important characteristics:
High-value patented medicines can generate enormous margins.
Successful drugs can remain commercially important for many years.
Patent expiration can create substantial revenue and earnings pressure.
This third factor is particularly important for MRK.
Merck Stock: 2025 Financial Performance
Merck reported $65.011 billion in worldwide sales in 2025, compared with $64.168 billion in 2024.
That represented:
Revenue growth: approximately 1%
Revenue growth excluding foreign exchange: approximately 2%
GAAP net income: $18.254 billion
Non-GAAP net income: $22.513 billion
GAAP EPS: $7.28
Non-GAAP EPS: $8.98
Merck's 2025 results therefore showed a company that remained highly profitable even though headline revenue growth was relatively modest.
Merck 2025 Financial Snapshot
| Metric | 2025 |
|---|---|
| Revenue | $65.0B |
| GAAP Net Income | $18.25B |
| Non-GAAP Net Income | $22.51B |
| GAAP EPS | $7.28 |
| Non-GAAP EPS | $8.98 |
| R&D Expense | ~$15.8B |
| Animal Health Revenue | $6.35B |
| KEYTRUDA Revenue | ~$31.64B |
| Gardasil/Gardasil 9 Revenue | ~$5.23B |
The most important observation is that KEYTRUDA alone generated approximately $31.6 billion in 2025 sales.
That means KEYTRUDA represented roughly 49% of Merck's total 2025 revenue.
This concentration explains both the bullish and bearish investment thesis for MRK.
KEYTRUDA Remains the Center of the MRK Investment Story
KEYTRUDA is one of the most successful oncology medicines ever commercialized.
Merck reported approximately $31.64 billion of KEYTRUDA sales in 2025, up from $29.48 billion in 2024.
That represented approximately 7% annual growth.
The product continued to benefit from expansion into earlier-stage cancers and additional indications.
During 2026, Merck received additional regulatory approvals involving KEYTRUDA, including U.S. approval in certain ovarian cancer patients and approval in combination with Welireg for certain renal cell carcinoma patients.
This is important because Merck does not necessarily need KEYTRUDA sales to collapse immediately after exclusivity changes.
The company is attempting to:
Expand KEYTRUDA into additional indications
Move treatment into earlier stages of disease
Increase utilization
Introduce KEYTRUDA QLEX
Combine KEYTRUDA with other therapies
Develop next-generation oncology products
This strategy could extend the economic value of the franchise.
The Biggest Risk: The KEYTRUDA Patent Cliff
The largest structural concern surrounding MRK is the future loss of exclusivity surrounding KEYTRUDA.
The market has been discussing this issue for years, and it remains one of the most important variables in any long-term Merck valuation.
The problem is simple.
If a medicine generates approximately $31.6 billion annually, even a partial loss of exclusivity can have a major effect on:
Revenue
Operating profit
EPS
Free cash flow
Dividend coverage
Valuation multiples
Merck itself expects KEYTRUDA to be selected for the U.S. government's Medicare drug-price negotiation program in 2027, with the negotiated price potentially becoming effective in 2029. Merck has challenged the IRA drug-price program in court.
Therefore, investors need to distinguish between two different risks:
Patent/exclusivity risk and government pricing risk.
They are related, but they are not identical.
The Inflation Reduction Act Adds Another Layer of Risk
The Inflation Reduction Act has changed the economics of pharmaceutical pricing in the United States.
Merck's 2026 Form 10-Q states that:
Januvia became subject to the Medicare negotiation price beginning January 1, 2026.
Janumet and Janumet XR have negotiated prices scheduled for 2027.
Lenvima has been selected for a future negotiated price beginning in 2028.
Merck expects KEYTRUDA to be selected in 2027 for a negotiated price effective in 2029.
For long-term investors, this creates another reason to focus on the company's product pipeline.
The more diversified Merck becomes, the less damaging the loss of pricing power on individual products should be.
Gardasil Is Another Important Investor Concern
Merck's second major franchise, Gardasil/Gardasil 9, experienced a substantial decline in 2025.
Worldwide Gardasil and Gardasil 9 sales fell approximately 39% to $5.23 billion in 2025.
The major issue was weaker demand in China, alongside other international market factors.
However, the trend began to improve in certain markets during 2026.
In Q2 2026, combined Gardasil and Gardasil 9 sales increased 4%, helped by higher demand in Asia Pacific and Europe and favorable European tender timing. However, sales for the first six months of 2026 were still down 9%, primarily because of lower demand in China and Japan.
This makes Gardasil a product investors should monitor rather than automatically classify as either a permanent decline or an immediate recovery.
Q2 2026 Shows Signs of Portfolio Transformation
Merck's Q2 2026 results were more encouraging.
The company reported:
Worldwide sales: $16.6 billion
That represented:
5% reported growth
4% growth excluding foreign exchange
KEYTRUDA/KEYTRUDA QLEX generated approximately $8.4 billion, representing 5% growth.
WINREVAIR generated $588 million, up 75%.
Animal Health generated approximately $1.8 billion, up 8%.
These numbers show why the long-term MRK thesis is broader than KEYTRUDA alone.
WINREVAIR Could Become an Important Growth Driver
WINREVAIR is one of Merck's newer growth products.
In Q2 2026, sales increased approximately 75% to $588 million.
The product is therefore still considerably smaller than KEYTRUDA, but its growth rate is much faster.
For investors, the significance is not that WINREVAIR can immediately replace KEYTRUDA.
It is that Merck is building multiple products capable of contributing billions of dollars of future revenue.
That diversification is essential to the post-KEYTRUDA investment thesis.
LIPFENDRA Adds Another Potential Growth Engine
Merck received U.S. FDA approval for LIPFENDRA (enlicitide), an oral PCSK9 inhibitor intended to reduce LDL cholesterol in adults with hypercholesterolemia.
Merck described it as the first and only once-daily oral PCSK9 inhibitor approved by the FDA for LDL-C reduction at the time of approval.
The commercial opportunity could be significant because cardiovascular disease represents a huge global healthcare market.
However, investors should avoid assigning blockbuster revenue to LIPFENDRA before actual commercial adoption becomes visible.
The important metrics will be:
Prescription growth
Insurance coverage
Pricing
Patient adherence
Physician adoption
Competition
Net revenue per patient
Merck's Pipeline Is the Key to the Long-Term Bull Case
Merck is aggressively investing in research and business development.
The company spent approximately $15.8 billion on R&D in 2025.
This is strategically important.
Pharmaceutical companies cannot simply defend their existing products.
They must continuously replace drugs that eventually face:
Patent expiration
Generic competition
Biosimilars
Pricing pressure
New therapeutic alternatives
Merck's pipeline includes programs in:
Oncology
HIV
Vaccines
Cardiometabolic disease
Immunology
Infectious disease
The company is also using acquisitions and licensing transactions to accelerate portfolio diversification.
Merck and Moderna's Cancer Vaccine Could Be a Major Catalyst
One of the most important recent developments is Merck's partnership with Moderna involving personalized mRNA cancer therapy.
In August 2026, Merck and Moderna announced positive Phase 3 interim results from the INTerpath-001 trial evaluating intismeran autogene in combination with KEYTRUDA in patients with completely resected stage IIB-IV melanoma.
The results showed significant improvement in recurrence-related endpoints and generated a strong market reaction.
For Merck investors, the significance goes beyond a single melanoma indication.
If personalized cancer vaccines ultimately become an important part of oncology treatment, KEYTRUDA could serve as the backbone of combination therapies.
That creates a potentially powerful strategic relationship:
KEYTRUDA + personalized cancer vaccine + additional oncology agents
rather than relying on KEYTRUDA as a standalone product.
However, investors should remain disciplined because complete clinical and long-term survival data are still important to evaluating the ultimate commercial opportunity.
What American Investors Are Saying About MRK
Investor discussions among U.S.-focused stock and dividend communities reveal a recurring pattern.
The bullish argument generally focuses on:
Strong cash generation
A large pharmaceutical franchise
KEYTRUDA's competitive position
Dividend income
Pipeline potential
Animal Health diversification
The possibility that the market has already discounted much of the patent-cliff risk
The bearish argument tends to focus on:
KEYTRUDA concentration
Patent expiration
Gardasil weakness
Medicare price negotiation
Pharmaceutical regulatory risk
M&A execution
Whether new products can replace billions of dollars of KEYTRUDA revenue
For example, discussions in U.S. investing communities have repeatedly described MRK as a potential value/dividend opportunity while simultaneously identifying KEYTRUDA's future exclusivity as the central risk.
More recent discussion has become somewhat more optimistic following positive Merck/Moderna cancer-vaccine results, although investors continue to debate whether the potential market opportunity justifies the stock's higher valuation.
This suggests that the typical American investor debate is not:
"Is Merck a good company?"
It is:
"Is Merck's future growth strong enough to justify the current stock price after accounting for KEYTRUDA risk?"
Dividend Analysis
Merck remains attractive to many income-oriented investors because of its quarterly dividend.
The company currently lists a quarterly cash dividend of $0.85 per share, with the September 2026 ex-dividend date scheduled for September 14 and payment scheduled for October 7.
That translates into an annualized dividend of approximately:
$0.85 × 4 = $3.40 per share
Using a share price around $150.33, the simple indicated dividend yield is approximately:
2.3%
This is not an exceptionally high yield compared with distressed pharmaceutical stocks.
But the more important consideration is dividend sustainability.
Merck's 2025 GAAP EPS was $7.28, while its annualized dividend based on the current quarterly payout is approximately $3.40.
That implies a rough GAAP EPS payout ratio of:
$3.40 / $7.28 ≈ 47%
On that basis, the dividend currently has meaningful earnings coverage.
Investors should nevertheless recognize that future payout ratios could rise if KEYTRUDA revenue declines faster than replacement products grow.
MRK Valuation: The Number That Requires Caution
At approximately $150 per share, MRK looks very different from the deeply discounted valuation investors discussed earlier in 2026.
The current market data shows a trailing P/E around 120x, although this figure is heavily distorted by accounting effects and acquisition-related items.
Therefore, investors should not use the headline trailing P/E as the sole valuation measure.
A better approach is to examine:
Forward adjusted EPS
Free cash flow
Dividend yield
Enterprise value
Product-level revenue growth
Pipeline probability
Post-KEYTRUDA earnings power
Merck's own Q2 2026 guidance expects full-year 2026 worldwide sales of approximately $66.3 billion to $67.3 billion.
The company also expects 2026 non-GAAP EPS of approximately $2.66 to $2.76, although this guidance includes significant acquisition-related charges associated with Terns Pharmaceuticals.
This is an important distinction.
Reported EPS and underlying operating earnings are currently being affected by business-development accounting charges.
Merck's 2026 Financial Outlook
 |
| Merck & Co., Inc. (MRK) |
Merck raised and narrowed its 2026 sales guidance in Q2.
Current full-year guidance:
| 2026 Metric | Outlook |
|---|---|
| Worldwide Sales | $66.3B–$67.3B |
| Non-GAAP EPS | $2.66–$2.76 |
| Q2 Sales | $16.6B |
| KEYTRUDA/QLEX Q2 Sales | $8.4B |
| WINREVAIR Q2 Sales | $588M |
| Animal Health Q2 Sales | $1.8B |
The sales outlook is encouraging because it indicates that Merck expects continued growth despite significant pressure within portions of the vaccine portfolio.
Bull Case for MRK Stock
The bullish case for Merck can be summarized in six points.
1. KEYTRUDA remains extraordinarily strong
A $31.6 billion annual franchise growing 7% is difficult to replace.
2. Merck is diversifying
WINREVAIR, CAPVAXIVE, LIPFENDRA, Animal Health and oncology pipeline programs provide additional growth opportunities.
3. Oncology remains a powerful long-term market
Cancer incidence and the demand for better targeted therapies support continued investment in oncology.
4. The pipeline could create a second growth cycle
The Merck/Moderna cancer-vaccine program is one example of how Merck can use KEYTRUDA as a foundation for next-generation combinations.
5. Dividend provides shareholder income
The dividend provides a tangible component of total return while investors wait for pipeline products to mature.
6. The company has financial scale
With approximately $65 billion of annual revenue and $15.8 billion of annual R&D spending, Merck has the resources to fund both internal research and external acquisitions.
Bear Case for MRK Stock
The bearish thesis is equally clear.
1. KEYTRUDA concentration is extremely high
Approximately half of 2025 revenue came from KEYTRUDA and KEYTRUDA QLEX.
2. Patent/exclusivity risk is approaching
Investors must prepare for a future period when KEYTRUDA growth becomes more difficult.
3. Government pricing creates additional pressure
The IRA could reduce the economic value of certain products, including future pressure on KEYTRUDA.
4. Gardasil remains vulnerable
The 39% sales decline in 2025 demonstrates how quickly international vaccine demand can change.
5. M&A creates execution risk
Acquisitions can accelerate portfolio diversification, but they can also create integration costs, debt requirements and accounting charges.
6. MRK is no longer an obvious deep-value stock
After the stock's significant recovery, investors should demand stronger evidence that future pipeline growth justifies the valuation.
MRK Stock: 2026 SWOT Analysis
| Strengths | Weaknesses |
|---|---|
| KEYTRUDA leadership | High KEYTRUDA concentration |
| Strong global pharmaceutical platform | Gardasil weakness |
| Large R&D budget | Patent/exclusivity risk |
| Animal Health diversification | Complex acquisition strategy |
| Established dividend | Exposure to drug-price regulation |
| Opportunities | Threats |
|---|---|
| LIPFENDRA | Generic/biosimilar erosion |
| WINREVAIR | Medicare price negotiation |
| Cancer vaccine | Oncology competition |
| HIV pipeline | Failed clinical trials |
| New acquisitions | Regulatory changes |
| Earlier-stage KEYTRUDA indications | Patent litigation |
Who Should Consider MRK Stock?
MRK may be more appropriate for investors who want:
Exposure to large-cap U.S. pharmaceuticals
Dividend income
Defensive healthcare exposure
A combination of income and potential capital appreciation
Exposure to oncology innovation
A multi-year investment horizon
It may be less suitable for investors looking for:
Extremely rapid revenue growth
Minimal pharmaceutical regulatory risk
Pure technology-style growth
A company without major patent-cycle exposure
Is Merck Stock a Buy in 2026?
The answer depends heavily on an investor's time horizon.
For a long-term investor, Merck remains one of the more interesting pharmaceutical companies because it has the financial resources, R&D capabilities and commercial infrastructure to build a post-KEYTRUDA portfolio.
For a short-term investor, the risk/reward equation is less straightforward because the stock has already appreciated significantly and expectations surrounding the pipeline are becoming more important.
The most important issue is valuation.
At roughly $150 per share, investors should not simply buy MRK because it appears cheaper than some high-growth healthcare stocks.
Instead, investors should ask:
How much of KEYTRUDA's future decline is already priced in?
Can WINREVAIR become a multibillion-dollar franchise?
Can LIPFENDRA achieve meaningful commercial adoption?
Will Gardasil stabilize?
Can the oncology pipeline produce replacement revenue?
Can the Moderna partnership create a new growth platform?
Can Merck maintain dividend growth while funding its pipeline?
My MRK Investment Framework
For a long-term investor, I would categorize Merck into three scenarios.
Bull Case
Merck successfully expands KEYTRUDA, WINREVAIR becomes a major growth product, LIPFENDRA gains meaningful market share, the cancer-vaccine platform succeeds, and acquisitions successfully diversify the portfolio.
Result: Strong long-term earnings recovery and potential multiple expansion.
Base Case
KEYTRUDA eventually declines, but new products, Animal Health, vaccines and acquisitions replace a substantial portion of lost revenue.
Result: Moderate long-term shareholder returns with dividends contributing significantly to total return.
Bear Case
KEYTRUDA erosion accelerates, Gardasil remains weak, pipeline products fail to achieve blockbuster status, and M&A produces limited returns.
Result: Lower earnings and dividend-growth pressure, potentially leading to valuation compression.
Final Verdict: Is MRK Stock Worth Watching?
Merck & Co. remains a high-quality pharmaceutical company, but MRK is no longer a simple defensive dividend stock.
The investment thesis has evolved.
Historically, investors could focus primarily on KEYTRUDA's extraordinary growth and Merck's dividend.
Today, investors must focus on what comes after KEYTRUDA.
That makes the pipeline more important than ever.
The encouraging news is that Merck is already showing evidence of portfolio transformation. Q2 2026 sales reached $16.6 billion, WINREVAIR grew 75%, Animal Health grew 8%, and KEYTRUDA continued to grow. The company also received important regulatory milestones for new products such as LIPFENDRA.
The biggest concern remains concentration.
KEYTRUDA generated approximately $31.6 billion of revenue in 2025, nearly half of Merck's total revenue.
Therefore, the next several years will determine whether Merck can transform from a KEYTRUDA-dominated pharmaceutical company into a diversified healthcare growth platform.
Overall Investor Assessment
| Category | Assessment |
|---|---|
| Business Quality | Strong |
| Revenue Stability | Strong |
| KEYTRUDA Franchise | Excellent |
| Dividend | Attractive |
| R&D Capability | Excellent |
| Growth Diversification | Improving |
| Patent Risk | High |
| Regulatory Risk | Moderate–High |
| Pipeline Potential | Promising |
| Valuation at ~$150 | Requires discipline |
| Long-Term Outlook | Moderately Bullish |
Bottom line: MRK can make sense as a long-term healthcare holding, particularly for investors who value pharmaceutical scale, dividends and pipeline optionality. But investors should not ignore the KEYTRUDA concentration and upcoming pricing/exclusivity challenges.
For a new investor, the better strategy may be to evaluate MRK using forward earnings and free cash flow rather than headline trailing P/E, and to consider buying in stages rather than treating one share price as a definitive entry point.
This article is for educational purposes only and does not constitute personalized investment advice. Pharmaceutical stocks can experience substantial volatility because of clinical-trial outcomes, regulatory decisions, patent litigation, pricing policy and product launches.
Primary Sources and References
Merck & Co. 2025 Annual Report / Form 10-K
Merck Q2 2026 Financial Results
Merck Q2 2026 Form 10-Q
Merck Investor Relations
U.S. Securities and Exchange Commission filings
Merck official dividend information
Reuters reporting on the Merck-Moderna cancer-vaccine program
The most important primary documents are Merck's 2025 Form 10-K and Q2 2026 Form 10-Q, which provide the underlying financial, product, regulatory and risk disclosures used in this analysis.
About the Author
David Mulyana is the founder and editor of WorldReview1989, an independent publication dedicated to finance, investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Personal Finance
- Investing & Stock Market
- Cryptocurrency & Blockchain
- Insurance
- Banking
- Real Estate
- Business & Entrepreneurship
- Digital Marketing
- Financial Technology (FinTech)
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks
Join Facebook Group